EUVIMEDEUVIMED entdecken
Crossref

2723-LB: Baseline Plasma Metabolites in Adults with Prediabetes Predict Persistent Prediabetes vs. Glucose Normalization following Lifestyle Intervention

PEACE ASUZU, FRANKIE B. STENTZ, NAWAJES MANDAL, SAMUEL DAGOGO-JACK

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-2723-lb ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von PEACE ASUZU und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: We determined whether plasma metabolites are associated with response to lifestyle intervention (LI) in people with prediabetes.

Methods

We studied 138 adults (76 Black, 62 White) with prediabetes who received LI for 5 years. Assessments included anthropometry, body fat, fasting and 2-hr plasma glucose, insulin sensitivity and secretion, and plasma metabolites (18 amino acids, 45 acylcarnitines, 54 ceramides/other sphingolipids) measured with LC-ms/ms.

Results

In all 59 participants reverted to normal glucose regulation (NGR), 69 had persistent prediabetes, and 10 developed T2D during LI. In logistic regression, the baseline predictors of persistent prediabetes versus NGR after LI (odds ratio (OR) per 1-SD) were 2hPG (2.042 [1.322-3.156], P=0.0013); ratios of ceramide C18:0/C18:1 (1.937 [1.239 - 3.028], P=0.0038) and ceramide C18:0/C16:0 (1.580 [1.049-2.381], P=0.029); and octenoylcarnitine (C8:1) (1.918 [1.083 - 3.399], P=0.026), adjusted for age, sex and race (Table). The predictive baseline metabolites showed significant associations with adiposity, insulin sensitivity, and insulin secretion.

Conclusion

In adults with prediabetes, higher baseline levels of 2hPG, octenoylcarnitine (C8:1), and stearic/oleic acid ceramide ratio (C18:0/C18:1) predicted persistent prediabetes versus reversion to normoglycemia following lifestyle intervention. Disclosure P. Asuzu: None. F.B. Stentz: None. N. Mandal: None. S. Dagogo-Jack: Consultant; Current; Abbott, Madrigal Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk. Funding National Institutes of Diabetes Digestive and Kidney Diseases grants (R01 DK067269, R01 DK128129)

Zitieren

APA

ASUZU, P., STENTZ, F. B., MANDAL, N., & DAGOGO-JACK, S. (2026). 2723-LB: Baseline Plasma Metabolites in Adults with Prediabetes Predict Persistent Prediabetes vs. Glucose Normalization following Lifestyle Intervention. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2723-lb

Vancouver

ASUZU P, STENTZ FB, MANDAL N, DAGOGO-JACK S. 2723-LB: Baseline Plasma Metabolites in Adults with Prediabetes Predict Persistent Prediabetes vs. Glucose Normalization following Lifestyle Intervention. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2723-lb

BibTeX
@article{ASUZU2026,
  author = {ASUZU, PEACE and STENTZ, FRANKIE B. and MANDAL, NAWAJES and DAGOGO-JACK, SAMUEL},
  title = {2723-LB: Baseline Plasma Metabolites in Adults with Prediabetes Predict Persistent Prediabetes vs. Glucose Normalization following Lifestyle Intervention},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-2723-lb}
}
Kostenlos starten →